Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3

Gioia, Dorit Di; Blankenburg, Irene; Nagel, Dorothea; Heinemann, Volker; Stieber, P.

doi:10.1016/j.cca.2016.07.014

Cited by 38 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a positive correlation between changes in CEA blood levels and response to treatment in patients with metastases of breast cancer. It is also a useful marker for early detection of recurrence and metastasis [ 50 – 53 ]. CEA overexpression corresponds positively with tumor clinicopathological features, such as tumor size, tumor grade and lymph node status [ 52 ].…”

Section: Biomarkers Of Metastatic Potential Of the Tumormentioning

confidence: 99%

Current biomarkers of canine mammary tumors

et al. 2018

View full text Add to dashboard Cite

Mammary tumors are the second most common neoplasia in dogs. Due to the high similarity of canine mammary tumors (CMT) to human breast cancers (HBC), human biomarkers of HBC are also detectable in cases of CMT. The evaluation of biomarkers enables clinical diagnoses, treatment options and prognosis for bitches suffering from this disease. The aim of this article is to give a short summary of the biomarkers of CMT based on current literature. Very promising biomarkers are miRNAs, cancer stem cells, and circulating tumor cells, as well as mutations of the breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2). Until now, the most studied and reliable biomarkers of CMT have remained antigen Ki-67 (Ki-67), endothelial growth factor receptor, human epidermal growth factor receptor 2 (HER-2), estrogen receptor, progesterone receptor and cyclooxygenase 1 (COX-2), which can be detected in both serum and tissue samples using different molecular methods. However, carcinoembryonic antigen and cancer antigen 15-3 (CA 15-3), while poorly studied, seem to be good biomarkers, especially for the early detection and prognosis of CMT. We will also mention the following: proliferative cell nuclear antigen, tumor protein p53 (p53), E-cadherin, vascular endothelial growth factor, microRNAs, cancer stem cells and circulating tumor cells, which can also be useful biomarkers. Although many studies have been conducted so far, the estimation of biomarkers in cases of CMT is still not a common practice, and more detailed research should be done.

show abstract

Section: Biomarkers Of Metastatic Potential Of the Tumormentioning

confidence: 99%

Current biomarkers of canine mammary tumors

et al. 2018

View full text Add to dashboard Cite

show abstract

“…for TBX3 level in tumour tissues compared to normal tissues. These methods were used by several studies to show the diagnostic value of tumour makers including carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), CA15-3 and tissue polypeptide-specific antigen (TPS) in metastatic breast cancer (27)(28)(29)(30).…”

Section: Tbx3 Is a Promising Diagnostic Marker For Breast Cancermentioning

confidence: 99%

Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer

et al. 2018

View full text Add to dashboard Cite

The T-box 3 (TBX3) transcription factor has been shown to serve multiple roles in normal development. Recent findings have revealed that TBX3 is overexpressed in different types of carcinomas, including breast, cervical, ovarian, melanoma, pancreatic, lung, liver, bladder, head and neck. Therefore, the present study investigated the significance of TBX3 as a diagnostic marker of breast cancer. To achieve this aim, breast cancer samples and their adjacent normal tissues were collected from 51 breast cancer patients from the European Gaza hospital during 2015-2016. Sections from each sample were immune-stained by anti-TBX3 and suitable secondary and tertiary antibodies. TBX3 levels were evaluated in cancerous and normal samples. Clinicopathological data for each patient were documented. The correlation between TBX3 levels and the clinicopathological parameters were statistically tested. The results revealed that TBX3 is significantly overexpressed in breast cancer tissues when compared with normal tissues. Furthermore, TBX3 was mainly a cytoplasmic protein in normal and breast cancer tissues. Notably, TBX3 levels exhibited a sensitivity of 78.4%, specificity of 79.6%, accuracy of 79% and area under the curve of 0.791 (0.700-0.882) at a cutoff value=9 as breast cancer marker. However, no significant associations were observed between TBX3 levels and other breast cancer markers including oestrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cancer antigen 15-3 and breast cancer stages. Altogether, these results suggested that TBX3 overexpression may be a potential biomarker for breast cancer.

show abstract

“…20 More recent studies measuring multiple biomarkers reported increased accuracy in detecting early recurrences. [21][22][23][24] Thus, by combining measurement of both CA 15-3 (with a cut-off value of .60 kU/L) and CEA (with a cut-off value of .10 mg/L) and excluding patients with locoregional recurrences, Molina et al 21 reported a sensitivity of 64% and specificity of 99% for detecting recurrent disease. Based on a confirmed 100% increase in biomarker levels, Stieber et al 22 reported that combined measurement of CA 15-3 and CEA detected early metastasis with a sensitivity of 66.3% and a specificity of .98%.…”

Section: Traditional Protein Biomarkersmentioning

confidence: 99%

“…22 Sensitivity, however, could be further enhanced by measuring additional biomarkers such as CA 125, sHER2, and CYFRA 21-1. 23 In another study that measured multiple biomarkers, Nicolini et al, 24 using individualized cut-off values, found that combined measurement of CA 15-3, CEA and TPA detected early recurrence with a sensitivity of 93% and a specificity of 97.6%.…”

Section: Traditional Protein Biomarkersmentioning

confidence: 99%

“…[17][18][19] The biomarkers most frequently measured in this setting are CA 15-3, CEA, tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and the soluble form of HER2 (sHER2). [20][21][22][23][24] A pooled analysis of early studies involving the postoperative measurement of CA 15-3 concluded that 67% of 352 asymptomatic patients had increased CA 15-3 concentrations either before or at the time of recurrence. 20 In 1320 patients lacking evidence of recurrence at the time of reporting, 92% had CA 15-3 concentrations within the reference ranges.…”

Section: Traditional Protein Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA

2018

View full text Add to dashboard Cite

Biomarkers are the key to personalized treatment in patients with breast cancer. While tissue biomarkers are most useful in determining prognosis and upfront predicting response to therapy, circulating protein biomarkers such as CA 15-3 and carcinoembryonic antigen are mainly used in monitoring response to endocrine or chemotherapy in patients with advanced disease. Although several centers measure biomarkers in asymptomatic patients following curative surgery for primary breast cancer, the clinical utility of this practice is unclear. Promising new biomarkers for breast cancer include circulating tumor DNA and circulating tumor cells. In contrast to circulating protein biomarkers, measurement of circulating tumor DNA-based biomarkers is potentially useful in identifying mechanisms of resistance to ongoing therapies as well as identifying new targets for further treatment. To increase clinical utility, both the established and emerging circulating biomarkers should where possible be incorporated into randomized trials evaluating new therapies in patients with breast cancer.

show abstract

Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3

Cited by 38 publications

References 47 publications

Current biomarkers of canine mammary tumors

Current biomarkers of canine mammary tumors

Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA

Contact Info

Product

Resources

About